jaguar.healthCrawled Oct 15, 2026
Jaguar licensed U.S. commercial rights to Mytesi and Canalevia-CA1 to Future Pak/Theratechnologies in January 2026. Mytesi is an FDA-approved antisecretory agent.
Jaguar Health develops prescription health solutions while responsibly harnessing plants.
Jaguar and its family companies, Napo Pharmaceuticals, Inc. and Napo Therapeutics S.p.A., are conducting a global development program for a powder for oral solution formulation of crofelemer for rare intestinal failure indications in adults.
Jaguar Health’s liquid oral therapy **crofelemer** reduces reliance on parenteral support for patients with congenital enteropathy disorder caused by *GUCY2C* gene mutations. The treatment shows no significant side effects and lowers daily and weekly dependency on intravenous nutrition. This marks the third rare intestinal failure (IF) condition—following microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF)—where crofelemer has demonstrated clinical benefit under expanded access.
Oct 2026Yahoo FinanceNews article
Jaguar Health distributes a special stock dividend of Series R Convertible Preferred Stock to holders of its common stock and warrants. CEO Lisa Conte emphasizes the company’s continued focus on expanding its global development initiatives. The move supports existing shareholders while reinforcing strategic growth plans.
Oct 2026FinanzwireNews article
Jaguar Health introduces **Neonorm Dog**, a plant-based, non-prescription product supporting normal stool consistency and gastrointestinal (GI) fluid balance in dogs. The product expands the Neonorm brand, previously available for foals and calves, to address canine digestive health. It is now available for purchase on Amazon.
Sep 2026Morningstar, Inc.News article
Jaguar Health is evaluating strategic options while preparing to file a New Drug Application (NDA) for its **crofelemer** program, targeting rare intestinal failure diseases. The company’s founder and CEO, Lisa Conte, will discuss updates on the development program at the **Life Sciences Virtual Investor Forum on June 24, 2026**. Crofelemer is a potential treatment for patients with severe intestinal absorption disorders.
Jun 2026Yahoo FinanceNews article
